Tibet Cheezheng Tibetan Medicine Co Ltd
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral tibetan medicines, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculo… Read more
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) - Net Assets
Latest net assets as of September 2025: CN¥4.85 Billion CNY
Based on the latest financial reports, Tibet Cheezheng Tibetan Medicine Co Ltd (002287) has net assets worth CN¥4.85 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.64 Billion) and total liabilities (CN¥1.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.85 Billion |
| % of Total Assets | 73.11% |
| Annual Growth Rate | 12.99% |
| 5-Year Change | 56.13% |
| 10-Year Change | 149.13% |
| Growth Volatility | 25.85 |
Tibet Cheezheng Tibetan Medicine Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Tibet Cheezheng Tibetan Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tibet Cheezheng Tibetan Medicine Co Ltd (2006–2024)
The table below shows the annual net assets of Tibet Cheezheng Tibetan Medicine Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.11 Billion | +9.10% |
| 2023-12-31 | CN¥3.77 Billion | +11.29% |
| 2022-12-31 | CN¥3.39 Billion | +5.19% |
| 2021-12-31 | CN¥3.22 Billion | +22.23% |
| 2020-12-31 | CN¥2.63 Billion | +16.48% |
| 2019-12-31 | CN¥2.26 Billion | +10.59% |
| 2018-12-31 | CN¥2.05 Billion | +8.00% |
| 2017-12-31 | CN¥1.89 Billion | +8.13% |
| 2016-12-31 | CN¥1.75 Billion | +6.07% |
| 2015-12-31 | CN¥1.65 Billion | +6.54% |
| 2014-12-31 | CN¥1.55 Billion | +7.01% |
| 2013-12-31 | CN¥1.45 Billion | +7.14% |
| 2012-12-31 | CN¥1.35 Billion | +5.80% |
| 2011-12-31 | CN¥1.28 Billion | +5.64% |
| 2010-12-31 | CN¥1.21 Billion | +5.65% |
| 2009-12-31 | CN¥1.14 Billion | +115.05% |
| 2008-12-31 | CN¥532.28 Million | +34.30% |
| 2007-12-31 | CN¥396.33 Million | -13.20% |
| 2006-12-31 | CN¥456.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Cheezheng Tibetan Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 681.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.38 Billion | 58.65% |
| Common Stock | CN¥531.09 Million | 13.07% |
| Other Comprehensive Income | CN¥134.35 Million | 3.31% |
| Other Components | CN¥1.02 Billion | 24.98% |
| Total Equity | CN¥4.06 Billion | 100.00% |
Tibet Cheezheng Tibetan Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Tibet Cheezheng Tibetan Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
$347.98 Million |
|
Semler Scientific Inc
NASDAQ:SMLR
|
$348.27 Million |
|
OPUS GLOBAL Nyrt
BUD:OPUS
|
$348.36 Million |
|
SK Networks Co Ltd
KO:001740
|
$348.44 Million |
|
ThredUp Inc
NASDAQ:TDUP
|
$347.81 Million |
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
$347.71 Million |
|
ZEAL Network SE
XETRA:TIMA
|
$347.60 Million |
|
Johnson Health Tech Co Ltd
TW:1736
|
$347.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Cheezheng Tibetan Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,720,328,772 to 4,064,375,038, a change of 344,046,266 (9.2%).
- Net income of 582,281,121 contributed positively to equity growth.
- Dividend payments of 282,448,745 reduced retained earnings.
- Other comprehensive income decreased equity by 2,900,071.
- Other factors increased equity by 47,113,961.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥582.28 Million | +14.33% |
| Dividends Paid | CN¥282.45 Million | -6.95% |
| Other Comprehensive Income | CN¥-2.90 Million | -0.07% |
| Other Changes | CN¥47.11 Million | +1.16% |
| Total Change | CN¥- | 9.25% |
Book Value vs Market Value Analysis
This analysis compares Tibet Cheezheng Tibetan Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.05x to 3.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.97 | CN¥24.25 | x |
| 2007-12-31 | CN¥0.84 | CN¥24.25 | x |
| 2008-12-31 | CN¥1.11 | CN¥24.25 | x |
| 2009-12-31 | CN¥2.30 | CN¥24.25 | x |
| 2010-12-31 | CN¥2.25 | CN¥24.25 | x |
| 2011-12-31 | CN¥2.36 | CN¥24.25 | x |
| 2012-12-31 | CN¥2.51 | CN¥24.25 | x |
| 2013-12-31 | CN¥2.70 | CN¥24.25 | x |
| 2014-12-31 | CN¥2.88 | CN¥24.25 | x |
| 2015-12-31 | CN¥3.06 | CN¥24.25 | x |
| 2016-12-31 | CN¥3.29 | CN¥24.25 | x |
| 2017-12-31 | CN¥3.56 | CN¥24.25 | x |
| 2018-12-31 | CN¥3.85 | CN¥24.25 | x |
| 2019-12-31 | CN¥4.25 | CN¥24.25 | x |
| 2020-12-31 | CN¥4.95 | CN¥24.25 | x |
| 2021-12-31 | CN¥5.99 | CN¥24.25 | x |
| 2022-12-31 | CN¥6.29 | CN¥24.25 | x |
| 2023-12-31 | CN¥7.02 | CN¥24.25 | x |
| 2024-12-31 | CN¥7.66 | CN¥24.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Cheezheng Tibetan Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.33%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.91%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.67x
- Recent ROE (14.33%) is below the historical average (17.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 23.29% | 39.55% | 0.45x | 1.30x | CN¥60.46 Million |
| 2007 | 29.31% | 34.14% | 0.66x | 1.30x | CN¥76.31 Million |
| 2008 | 25.57% | 32.84% | 0.65x | 1.19x | CN¥82.69 Million |
| 2009 | 14.07% | 34.27% | 0.36x | 1.13x | CN¥46.50 Million |
| 2010 | 14.35% | 32.55% | 0.40x | 1.11x | CN¥51.69 Million |
| 2011 | 13.72% | 21.63% | 0.58x | 1.09x | CN¥46.25 Million |
| 2012 | 14.39% | 20.36% | 0.65x | 1.08x | CN¥58.06 Million |
| 2013 | 15.15% | 22.01% | 0.63x | 1.09x | CN¥72.50 Million |
| 2014 | 15.79% | 25.00% | 0.53x | 1.19x | CN¥87.12 Million |
| 2015 | 16.44% | 26.63% | 0.48x | 1.28x | CN¥103.80 Million |
| 2016 | 16.71% | 29.93% | 0.47x | 1.20x | CN¥116.41 Million |
| 2017 | 16.03% | 28.57% | 0.46x | 1.22x | CN¥113.14 Million |
| 2018 | 15.71% | 26.27% | 0.52x | 1.14x | CN¥115.84 Million |
| 2019 | 16.22% | 25.97% | 0.47x | 1.33x | CN¥139.70 Million |
| 2020 | 15.43% | 27.20% | 0.33x | 1.70x | CN¥142.15 Million |
| 2021 | 22.59% | 40.43% | 0.32x | 1.76x | CN¥398.97 Million |
| 2022 | 14.16% | 23.11% | 0.35x | 1.76x | CN¥138.94 Million |
| 2023 | 15.62% | 28.42% | 0.32x | 1.69x | CN¥209.17 Million |
| 2024 | 14.33% | 24.91% | 0.34x | 1.67x | CN¥175.84 Million |
Industry Comparison
This section compares Tibet Cheezheng Tibetan Medicine Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,108,499,302
- Average return on equity (ROE) among peers: 13.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | CN¥4.85 Billion | 23.29% | 0.37x | $347.95 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |